Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toxoplasmosis Titers and past Suicide Attempts Among Older Adolescents Initiating SSRI Treatment.

Archives of suicide research : official journal of the International Academy for Suicide Research·2016

Same author

Diabetes insipidus.

The Journal of clinical endocrinology and metabolism·2013

Same author

Hyperprolactinemia and infertility.

Endocrinology and metabolism clinics of North America·2011

Same author

Patient guide to hyperprolactinemia diagnosis and treatment.

The Journal of clinical endocrinology and metabolism·2011

Same author

[Primary hyperparathyroidism due to an intrathoracic parathyroid adenoma. - A case report and review of the literature].

Laeknabladid·2010

Same author

Hyperprolactinemia.

Pituitary·2008

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Management of resistant prolactinomas.

Agusta Olafsdottir¹, Janet Schlechte

¹Division of Endocrinology and Metabolism, Department of Internal Medicine at the University of Iowa in Iowa City, IA 52242, USA.

Nature Clinical Practice. Endocrinology & Metabolism

|October 7, 2006

Summary

Dopamine agonist resistance in prolactin-secreting pituitary tumors is linked to D2 receptor loss. Cabergoline is effective when other agonists fail, with surgery or radiation reserved for refractory cases.

More Related Videos

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

Related Experiment Videos

Last Updated: Jul 19, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

Area of Science:

Endocrinology
Neurosurgery
Oncology

Background:

Prolactin-secreting pituitary tumors (prolactinomas) can become resistant to dopamine agonist therapy.
This resistance is often associated with a loss of pituitary D2 receptors.
Resistance occurs in both microadenomas and macroadenomas.

Purpose of the Study:

To review treatment strategies for dopamine agonist-resistant prolactinomas.
To highlight the efficacy of different dopamine agonists and alternative therapies.

Main Methods:

Review of existing literature on dopamine agonist resistance in prolactinomas.
Analysis of treatment outcomes for various therapeutic interventions.

Main Results:

Cabergoline demonstrates superior efficacy compared to other dopamine agonists like bromocriptine and quinagolide.
Tumors resistant to other agonists frequently respond to cabergoline.
Treatment goals focus on restoring gonadal and neurological function, not solely on normalizing prolactin levels or reducing tumor size.

Conclusions:

Maximizing dopamine agonist dosage, switching agonists (especially to cabergoline), or considering surgery/radiation are key treatment options.
Trans-sphenoidal surgery is indicated for patients intolerant to or failing medical therapy.
Radiation therapy is a last resort for medically and surgically refractory prolactinomas.